**Name of Journal: *World Journal of Diabetes***

**ESPS Manuscript NO: 23075**

**Manuscript Type: Minireviews**

**Infantile onset diabetes mellitus in developing countries - India**

Varadarajan P. Diabetes mellitus, Infants, genetics, presentation management

**Poovazhagi Varadarajan**

**Poovazhagi Varadarajan,** Department of Pediatrics, Chengalpattu Medical College and Hospital, Chengalpattu, Tamil Nadu 603001, India

**Author contributions:** Varadarajan P was the only author for this review.

**Conflict-of-interest** **statement:** None.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Correspondence to:** **Dr. Poovazhagi Varadarajan, Professor** of Pediatrics, Department of Pediatrics, Chengalpattu Medical College and Hospital, 8/11 Manjolai Street, Kalaimagal Nagar, Chengalpattu, Tamil Nadu 603001, India. poomuthu@yahoo.com

**Telephone:** +91-44-22251515

**Received:** October 18, 2015

**Peer-review started:** October 20, 2015

**First decision:** November 11, 2015

**Revised:** December 14, 2015

**Accepted:** January 21, 2016

**Article in press:**

**Published online:**

**Abstract**

Infantile onset diabetes mellitus (IODM) is an uncommon metabolic disorder in children. Infants with onset of diabetes mellitus (DM) at age less than one year are likely to be transient or permanent neonatal DM or rarely Type 1 diabetes. Diabetes with onset below 6 mo is a heterogeneous disease caused by single gene mutation. Literature on IODM is scanty in India. Nearly 83% of IODM present with diabetic keto acidosis (DKA) at the onset. Missed diagnosis was common in 67% of infants with diabetes. Potassium channel mutation with sulphonylurea responsiveness is the common type in the non-syndromic IODM and Wolcott Rallison syndrome is the common type in syndromic diabetes. Developmental delay and seizures were the associated co-morbid states. Genetic diagnosis has made a phenomenal change in the management of IODM. Switching from subcutaneous insulin to oral hypoglycemic drugs is a major clinical breakthrough in the management of certain types of monogenic diabetes. Mortality in neonatal diabetes is 32.5% during follow up from Indian studies. This article is a review of neonatal diabetes and available literature on IODM from India.

**Key words:** Infants; Diabetes mellitus; Monogenic diabetes; Co-morbid state; Mortality

**© The Author(s) 2016.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Infantile onset diabetes mellitus (IODM), the clinical presentation as syndromic and non syndromic forms from South India are discussed in this article. Associated co morbid states, mortality pattern, difficulty in the management and need for genetic evaluation among this group of infants is discussed. Identification of this form of monogenic diabetes by clinical evaluation and appropriate genetic evaluation to identify the subtypes helps in the management of these infants to improve the overall morbidity and mortality. Reported mortality in IODM is high from South India.

Varadarajan P. Infantile onset diabetes mellitus in developing countries - India. *World J Diabetes* 2016; In press

**INTRODUCTION**

Infantile onset diabetes includes all children with onset of diabetes at less than one year of age. Onset of diabetes in the first 6 mo of life is termed neonatal diabetes[1]. Majority of the neonatal diabetes are monogenic. However recent reports have suggested evaluation for monogenic diabetes among those with onset in later infancy (onset between 6 months and one year) too[2]. The two phenotypes of neonatal diabetes include transient neonatal diabetes (TNDM) and permanent neonatal diabetes (PNDM). The reported incidence of neonatal diabetes varies from 1 in 200000 to 1 in 400000[3]. Infants with PNDM continue to require insulin for maintaining euglycemia. TNDM usually resolves by 18 mo of age. In a study from Chennai in India, the occurrence of infantile onset diabetes was 7.9% among all diabetic children in a pediatric diabetic clinic[4]. Another hospital based retrospective data from south India revealed the incidence to be 7%[5]. A recent international cohort study used comprehensive genetic testing to identify causal mutations which were found in nearly 80% of samples in neonatal diabetes[6]. This indicated that genetic diagnosis results in a phenomenal change in the management of infantile onset diabetes.

 **Genetics of transient neonatal DM**

 Among the neonatal diabetes, 50%-60% of affected neonates are due to TNDM based on the western literature[7,8]. However in a study from Chennai in India, TNDM only accounted for 5% of all neonatal DM[4]. TNDM is commonly due to a developmental defect in the pancreatic beta cell function. The common genetic defect (60%-70%) is due to mutations in chromosome 6q 24[3,9,10]. The cause seems to be a defect in maternal methylation, most often due to recessive mutations in the ZPF57 (Zinc Finger Protein) gene[11]. There are 3 types of abnormalities leading to over-expression of the paternal allele at this locus: (1) a paternally inherited duplication; (2) paternal uniparental disomy (UPD); and (3) an epimutation resulting in a complete loss of methylation of the maternal allele at chromosome 6q24[12,13]. Mutations in KCNJ11 (Potassium channel subfamily J member 11) and ABCC8 (ATP binding cassette transporter subfamily C, member 8) leading to TNDM is about 20%-25%[13-16]. Rarely mutations in HNF 1B, insulin gene and solute carrier 2 family 2 gene (SLC2A2) can result in neonatal diabetes. TNDM remits permanently or may relapse later during adulthood. Thus TNDM may be a permanent beta cell defect with variable expression during growth and development. The clinical presentation includes hyperglycemia, dehydration, failure to thrive, and with or without ketoacidosis. The associated features in chromosome 6q 24 mutations include macroglossia (35%), umbilical hernia (14%) or more rarely cardiac and brain developmental defects. Infants with TNDM resulting from a KATP channel mutation are often heavier than patients with chromosome 6q24 TNDM at birth, are diagnosed with diabetes later, remit later and relapse earlier[17]. Chromosome 6q24 induced TNDM should be treated by insulin. Relapse due to UPD chromosome 6 mutation or ABCC8 mutation in puberty respond well to sulphonylurea therapy[18,19]. Relapsing diabetes due to 6q 24 related diabetes has been successfully treated by dipeptidyl peptidase 4 inhibitor[20]. The majority (> 90%) of TNDM due to ABCC 8/KCNJ11 mutation respond to sulphonylurea therapy[21]. Infants born with TNDM harbour a greater risk of developing type 2 diabetes later in the life[22]. There were only few researches, most were case reports about TNDM among Indian literatures[23-29]. Rarely encountered is Type 1 diabetes in infancy especially in the non-syndromic diabetes with onset in later part of infancy[30].

**Genetics of permanent neonatal DM**

Children with PNDM have their onset in early infancy and continue to be hyperglycemic which needs lifelong insulin therapy. The genetic defect involves mutation of genes involving the pancreatic B cell development, function, apoptosis and insulin molecule. Nearly 40% of the defect is in the genes regulating the K ATP (potassium ATP) channel. As early as 1997 mutations leading to PNDM have been described. The first being pancreatic agenesis due to mutations in IPF/Pancreatic and duodenal homeobox 1 (PDX1). Between 2004 and 2007 the mutations of KCNJ11, ABCC8 and INS genes were identified for PNDM. KCNJ11 and ABCC8 mutations account for nearly 40%-50% of all PNDM[31]. PNDM can be nonsyndromic or syndromic (Associated with other systemic features). The five genes in which mutations in nonsyndromic PNDM occur include KCNJ11 (approximately 30% of NDM), ABCC8 (approximately 19%), INS (approximately 20%), GCK (approximately 4%), and PDX1 (< 1%)[32]. The [mode of inheritance](http://www.ncbi.nlm.nih.gov/books/n/gene/glossary/def-item/mode-of-inheritance/) of PNDM is [autosomal dominant](http://www.ncbi.nlm.nih.gov/books/n/gene/glossary/def-item/autosomal-dominant/) for mutations in KCNJ11, autosomal dominant or [autosomal recessive](http://www.ncbi.nlm.nih.gov/books/n/gene/glossary/def-item/autosomal-recessive/) for mutations in ABCC8 and INS, and autosomal recessive for mutations in GCK and PDX1.

**KATP CHANNEL MUTATION**

Glucose sensing and insulin release from beta cells is a complex process. Glucose enters through GLUT receptors and generates energy in the form of ATP. This increased ratio of ATP to ADP results in closing of the potassium channels and depolarization. This activates the calcium channels and influx of calcium into cells leading to release of insulin by exocytosis. The potassium channel subunit Kir 6.2 (potassium inward receptor) and SUR (sulphonylurea receptor 1) are encoded by genes called KCNJ11 and ABCCC8. Mutations in these two genes are common in PNDM. Majority of these children respond to sulphonylurea, which acts on the potassium channels and keeps them open and prevent depolarization[33]. These channels are present in non-pancreatic tissues like brain, heart and skeletal muscles and this explains the associated co morbid states like developmental delay, muscle weakness and seizures etc. in DEND syndrome -Developmental delay, Epilepsy, Neonatal diabetes)[34,35]. A number of patients with KATP channel mutations present with a milder phenotype without epilepsy (termed intermediate DEND (iDEND) syndrome[36-38]. Infants or children with Kir mutation respond well to sulphonylurea therapy and is preferred than insulin as sulphonylurea therapy is associated with improvement of other systemic features along with glycemic control[39]. Among the published data from south India out of the 9 identified mutations 7 were due to KCNJ11 and ABCC8 mutation and successful switch was done in these children following genetic reports except one child with ABCC8 mutation induced hyperinsulinemic hypoglycemia[40].

**INSULIN**

*Insulin* gene defects lead to defective folding of insulin in the endoplasmic reticulum and this affects the insulin release. They may present as NDM or as MODY[41]. These infants do not have any extra pancreatic features. The heterozygous form presents during the first 6 months of age and 50% have keto acidosis. The more severe form with homozygous mutation presents much earlier and have low birth weight. Management includes insulin, prevention of hyperglycemia through diet and use of insulin sensitizers like metformin. Sulphonylureas are not effective. Insulin gene mutations leading to neonatal diabetes has been described even in Indian infants[40,42,43].

**GLUCOKINASE**

Glucokinase (GCK) is the glucose sensor of the cell. It essential for phosphorylation of the glucose molecule that enter the cells. Mutations lead to defective glycolytic activity and thereby the cascade leading to insulin release is affected. Homozygous infants present with neonatal diabetes. They need lifelong insulin therapy. Heterozygotes may present later as MODY 2 (maturity onset diabetes in young). Homozygous GCK mutation has been described in an infant from Chennai[4,43]. Though GCK mutations in neonates do not respond well to sulphonylurea, there are a few case reports suggesting a role for glibenclamide along with insulin in children with homozygous GCK mutation[44,45].

**PDX1**

The homozygous form presents as PNDM and has both pancreatic exocrine and endocrine dysfunction. The heterozygous form present as MODY 4[46].

Syndromic causes of permanent neonatal DM are due to mutations in *GATA6*, *PTF1A*, *FOXP3*, *GLIS3*, *RFX6*, *NEUROD1*, *NEUROG3*, *HNF1B*, *PAX6*, *SLC19A2* and *WFS1* gene.

**MUTATIONS IN *GATA6* GENE**

This is the most common cause for pancreatic agenesis. Extra pancreatic features are common and include structural heart defects, biliary tract and gut anomalies, and other endocrine abnormalities. Inheritance is [autosomal dominant](http://www.ncbi.nlm.nih.gov/books/n/gene/glossary/def-item/autosomal-dominant/), but in most reported cases the mutations have arisen de novo[47]

**PANCREATIC TRANSCRIPTION FACTOR 1, Α SUBUNIT**

This factor is essential for pancreatic development and function as well as cerebellar development. Other than pancreatic hypoplasia, they can have cerebellar hypoplasia, microcephaly and respiratory distress[48].

*FOXP3* gene mutation (Immune dysregulation, polyendocrinopathy and enteropathy, X-linked-IPEX syndrome). Though autoimmune diabetes is uncommon in infancy most of the autoimmune children may be due to FOXP3 mutations[49]. The IPEX syndrome gene on the X chromosome, which codes for a forkhead domain-containing protein known as “scurfin” is required for immune homeostasis. These children present with intractable diarrhea with villous atrophy, exfoliative dermatitis, autoimmune hypothyroidism, hemolytic anaemia and recurrent infections. They may be tested positive for islet cell auto antibodies

**GLI SUBFAMILY OF KRUPPEL-LIKE ZINC FINGER PROTEIN-3**

This transcription factor is involved in various processes multiple tissues. These infants present with multisystem involvement like diabetes, congenital hypothyroidism, congenital glaucoma, renal cysts and dysmorphic facies[50].

Other causes for syndromic neonatal diabetes include the following: MNX1 motor neuron disease pancreas homeobox I - Neonatal diabetes with developmental delay, neurogenic bladder, sacral agenesis, imperforate anus. NKX2-NK homeobox 2 - Neonatal diabetes with developmental delay, hypotonia, hearing impairment, cortical blindness and short stature. *RFX6* mutation has pancreatic hypoplasia, intestinal atresia, and gall bladder hypoplasia[51]. Pancreatic exocrine function is normal. Inheritance is autosomal recessive. NEUROD1 mutation present with cerebellar hypoplasia, sensorineural deafness, and visual impairment[52]. Pancreatic exocrine function is normal and the inheritance is autosomal recessive. NEUROG3 present with congenital malabsoptive diarrhea and the exocrine pancreatic function may be affected[53]. Inheritance is autosomal recessive. HNF 1 beta mutations present with hypo plastic pancreas and renal abnormalities. The inheritance is autosomal recessive with incomplete penetrance. PAX 6 mutations present with microcephaly and panhypopituitarism in central nervous system phenotype. The ocular phenotype includes aniridia, keratopathy, optic nerve defects, cataracts, microphthalmia and anophthalmia. Wolfram syndrome - DM with optic atrophy, diabetes insipidus and/or deafness, usually this presents little later in life though can present in the neonatal period. Optic atrophy and diabetes may present in the first decade of life while diabetes insipidus and deafness present later in 3rd or 4th decade[32]. SLC19A2 (Soluble carrier family 19, member 2) - Thiamine transporter mutations. Recessive mutations lead to neonatal diabetes, thiamine responsive megaloblastic anemia and deafness. They may have cardiac manifestations

This is also called Rogers syndrome and is inherited as an autosomal recessive disorder[54,55]. SLC2A2 (Soluble carrier family 2 member 2) - Fanconi bickel syndrome.

DM with hepatomegaly, glycosuria, proteinuria, hypophosphatemic rickets are the presenting features[56]. EIF2AK3 Eukaryotic translation initiation factor - 2 kinase Wolcott-Rallison syndrome. Infants with EIF2AK mutation present with neonatal diabetes, liver failure, growth retardation, epiphyseal dysplasia, developmental delay, hypothyroidism and renal failure. Higher mortality has been reported among these children. This is more common in infants born of consanguinity. Mortality is predominantly due to liver cell failure is these children[4,40].

The course of PNDM varies by [genotype](http://www.ncbi.nlm.nih.gov/books/n/gene/glossary/def-item/genotype/). Pancreatic agenesis/hypoplasia caused by homozygous mutations in *PDX1* results in severe insulin deficiency and exocrine pancreatic insufficiency. The morbidity and mortality varies according to the co morbid conditions of the infant. Rarely congenital hyperinsulinemia can present with neonatal diabetes with ABCC8 mutation but refractory to insulin therapy as in congenital lipodystrophy[57].

**CLINICAL PRESENTATION OF NDM**

Clinical features of both transient and permanent neonatal diabetes are indistinguishable. Neonatal Diabetes often presents with hyperglycemia incidentally identified during evaluation for intercurrent illness or may present with keto acidosis. Rarely candida infection of the genitalia a higher incidence of consanguinity was encountered in the study of 12 children with infantile diabetes from Chennai, India. Initial presentation as DKA was encountered in 83% of the study group. Mortality in 1 year follow up was 16.6%[5]. Another study by Poovazhagi *et al*[4] from south India revealed 67.5% of infants with ketotic onset. The median age at diagnosis was 3.75 months. Based on the study published from south India only 32% of infants were diagnosed to have diabetes or diabetic keto acidosis (DKA) at presentation. Missed diagnosis was common in 67.5% of infants with diabetes. Infantile onset diabetes present with history of polyuria, polydipsia, irritability, vomiting, seizures, breathlessness, poor feeding, white discharge from genitals, and sticky urine. Low birth weight and monogenic diabetes were more common in those infants with onset at less than 6 mo of age in comparison with those with onset beyond 6 mo. Sixty-three percent of infants with onset in the first 6 mo of life were of low birth weight. Eighty-five percent of infants with onset less than 6 mo were identified to be monogenic in comparison to 55% if the onset was more than 6 mo. This study revealed Wolcott Rallison to be most common type of monogenic diabetes[4]. This is similar to study by Ganesh *et al*[5] where 50% of the study group were Wolcott Rallison syndrome. Among the non syndromic type KCNJ11/8 was common and among the syndromic type Wolcott Rallison was common. Ten percent (4 out of 40) of infants had transient neonatal diabetes with remission of hyperglycemia in the first few months and one of them relapsed at 9.7 years of age. Children with Wolcott Rallison syndrome had higher mortality than any other group. Hepatic failure was the commonest cause of death. Co morbid states encountered in infants with diabetes include, developmental delay, seizures, hepatic involvement, hypothyroidism, optic atrophy, hepatomegaly, short stature and rickets. The mean insulin requirement was 1.19 units/kg per day in those with onset less than 6 mo or 1.4 units/kg per day in those with onset more than 6 mo. Among those children with KCNJ11 or ABCC8 mutation the response to oral sulphonylurea is excellent and better metabolic control has been documented even during follow up. Other than glibenclamide, glyburide has also been tried in children with KCNJ11 or ABCC8 mutation. Relapsing neonatal diabetes in older children do respond well with sulphonylurea without need for insulin therapy. Despite the advances of diagnosis and management of infantile onset diabetes, day to day problems exist in the management in developing countries. One of the problems of concern is the assessment of glycemic control among infants who are on 2-3 hourly breast feeds or demand feeds. Difficulty in dispensing very low doses of insulin is a problem in developing countries. Delivering insulin less than 1 unit is difficult as there are no diluents available in developing countries. Dilution with normal saline have been used in such situations but the evidence for the same to be effective is lacking. Currently available insulin pens to dispense 0.5 units may be useful in such infants. The psychological trauma to the family members and lack of adequate support in the community through a structured diabetic care team makes day to day management of diabetes difficult in these infants. Frequent hospitalization, glycemic fluctuations, poor weight gain and co morbid conditions were other problems reported in studies from south India[4]. Literature reveals continuous subcutaneous infusion of insulin as an useful intervention, though affordability and cost are limiting factors in developing countries. Limited availability of genetic studies in India may cause delay in the diagnosis of monogenic diabetes. Reported mortality in infantile onset diabetes is very high in developing countries. The mortality in 1 year follow up was 16%[5]. However another study of 40 infant with diabetes from south India had revealed a mortality of 32.5% over a 12 year period[4]. Cerebral edema, sepsis, acute respiratory distress syndrome, disseminated intravascular coagulation, hypoglycemia, refractory cardiac failure, septic shock, renal failure and hepatic failure were the causes of mortality in infantile onset diabetes.

Comparing the literature about IODM in developed countries, the following needs to be emphasized. Transient neonatal diabetes is reported to constitute 40%-60% of IODM in western literature while it is less than 10% from developing countries. The infrequent sequencing for 6q mutations may be a possible explanation. Those with onset between 6 to 12 mo were commonly identified to have *INS* gene mutation in comparison to the EIF2AK mutation in developing countries, a higher rate consanguinity may be a contributory factor. Comprehensive genetic testing has identified genetic cause in more than 80% of IODM’s in developed countries, while it is much lower in developing countries. Nearly 60%-80% if IODM present with DKA in developing countries while no such data is available from developed countries. Developmental delay and neuropsychological dysfunction is common in children with IODM from developed countries while developmental delay and hepatospleenomegaly have been reported from developing countries. Insulin pumps have been used for insulin requiring mutations in developed countries while they have been managed with conventional injections in developing countries like India. Overall mortality in IODM was reported to be 33% in developing countries while no such data on mortality in IODM is available from developed countries.

**DIAGNOSTIC APPROACH TO INFANTILE ONSET NEONATAL DIABETES**

A low c peptide level and high HBA1c level are supporting lab parameters to confirm infantile onset diabetes from stress induced hyperglycemia in infants. Initial evaluation should include a search for syndromic features. Look for associated features like hypothyroidism, elevated liver enzymes, skeletal dysgenesis, pancreatic agenesis, enteropathy, developmental delay, anemia, umbilical hernia and macroglossia (Table 1). All infants with onset of diabetes at less than one year of age need to undergo genetic evaluation at the earliest for monogenic diabetes. Older children of any age with infantile onset diabetes can undergo genetic work up as therapy with sullphonylurea at a later age is still useful for good glycemic control and management of other comorbid factors. However long term insulin therapy may reduce the available beta cell mass and they may need additional glucose reducing drugs. Hence an earlier genetic confirmation or therapy with sulphonylurea is warranted. Comprehensive genetic screening has been found to be more useful for early diagnosis than the conventional genetic screening. Conventional genetic tests analyze few genes based on the clinical features. With improved sequencing methods simultaneous analysis of multiple genes is possible. The genetic result predicts the best diabetes treatment and development of associated features. Evaluation with auto immune antibodies may be warranted in infants with onset of diabetes in late infancy as the chances of type 1 diabetes presenting in late infancy have been reported in literature.

***Management of infantile onset diabetes***

Adequate hydration of infants with acute presentation in DKA is essential. Infants with DKA may need much more fluids than the management of older children. Associated predisposing factors like sepsis or bronchopneumonia need to be treated for early control of hyperglycemia. Infusions of short acting insulin in DKA and subcutaneous doses of insulin is the therapy of choice until evaluation for monogenic diabetes. These infants and toddlers may be very sensitive to small doses of insulin and careful watch for hypoglycemia is a must. Avoiding hypoglycemia is essential in these infants as sequelae of hypoglycemia on developing brain leads to increased morbidity. Short acting and rapid acting insulin may sometimes cause hypoglycemia that is difficult to control in infants. Intermediate acting insulin is preferred to be given as once or twice a day therapy[4]. Initial insulin dose for stabilization may range from 0.35 units/kg per day to 3 units/kg per day. Insulin pumps have been used successfully in developed countries[58,59], but the initial cost and subsequent maintenance are major issues is using insulin pumps in infants from developing countries like India. If genetic reports suggest mutation in KCNJ11 or ABCC8 mutation which are responsive to sulphonylurea transfer to oral drugs should be undertaken. Earlier identification of sulphonylurea responsiveness (KCNJ11 and ABCC8 mutations) is essential as the insulin therapy will only achieve glycemic control. Other systemic manifestations like seizures, muscular involvement, and developmental delay do not respond to insulin therapy. Earlier institution of sulphonylurea is essential to prevent worsening of these co morbid factors in IODM. Following genetic confirmation insulin can be switched slowly by outpatient protocols or by rapid inpatient protocols[21,60-66]. The initial median dose for sulphonylurea used to treat patients with KATP channel mutations is 0.45 mg/kg per day range 0.05-1.75 mg/kg per day. The switch over from insulin therapy to sulphonylurea may take more than 6 weeks as some infants need very high doses up to 2 mg/kg per day of sulphonylurea[4]. In developing countries like India awaiting genetic reports for sulphonylurea therapy may cause a delay in specific treatment for co morbid conditions. Studies have been undertaken to assess the risk and benefit of sulphonylurea therapy prior to genetic confirmation. In view of the potential benefit in the neurodevelopmental outcome and glycemic control one may consider empirical inpatient trial with sulphonylurea if the genetic results are likely to be delayed. However further studies on large number of infants are warranted to decide on empirical sulphonylurea therapy[67]. Age at initiation of sulphonylurea showed a linear correlation with the dose required at follow up. Indeed, all patients required additional glucose lowering medications along with sulphonylurea, if drug therapy was started at age 13 years or older[68]. Short term studies on sulphonylurea therapy in children have been found to be safe without major side effects. Diarrheal episodes and rarely discolouration of teeth have been reported with sulphonylurea. Diarrhea usually disappears with therapy. None of these side effects will affect continuation of therapy[63,69]. It is imperative to confirm the genetic mutation to decide treatment, to assess prognosis and anticipate the long term outcome. They need to be followed up even after remission as relapse has been reported in early adolescence or adults. The relapse responds well to sulphonylurea therapy.

These children need to be followed up for glycemic control, growth pattern, developmental delay, seizures, pancreatic exocrine function, hypothyroidism and other comorbid states depending on the type of mutation. Periodic monitoring for long term complications is mandatory. Presently there are no guidelines for long term follow up for diabetes related complications in these children with infantile onset diabetes, as long term follow up studies are lacking. Evaluation of the parental diabetic status and the genetic mutations will help to plan counseling regarding the future conceptions in the family. A neonatal diabetes registry has been established in India where facilities are available to sequence KCNJ11, ABCC8 insulin genes and other syndromic mutations.

**CONCLUSION**

DKA is the commonest presentation of infantile onset diabetes in 67%-83%. Low birth weight is common in infants less than 6 mo of age at presentation. Sixty-seven point five percent of IODM had a missed diagnosis at presentation. Monogenic diabetes is the commonest cause of infantile onset diabetes. KCNJ11/ABCC8 and EIF2AK mutations are the commonly reported non. Syndrome and syndromic types respectively. Transient neonatal DM was noted in 10% of all infantile onset diabetics in south India. Developmental delay and seizures are major co morbid factors in IODM. Glycemic control assessment among breast fed infants and dispensing very small doses of insulin are difficult in IODM in developing countries. Management is by once or twice a day injections of intermediate acting subcutaneous insulin, continuous subcutaneous insulin infusions if feasible. Potassium channel mutations (KCNJ11 and ABCC8) are sulphonylurea responsive and infants may need higher doses up to 2 mg/kg per day. Reported mortality during follow up of IODM is very high (33%) in India.

**REFERENCES**

1 **Aguilar-Bryan L**, Bryan J. Neonatal diabetes mellitus. *Endocr Rev* 2008; **29**: 265-291 [PMID: 18436707 DOI: 10.1210/er.2007-0029]

2 **Mohamadi A**, Clark LM, Lipkin PH, Mahone EM, Wodka EL, Plotnick LP. Medical and developmental impact of transition from subcutaneous insulin to oral glyburide in a 15-yr-old boy with neonatal diabetes mellitus and intermediate DEND syndrome: extending the age of KCNJ11 mutation testing in neonatal DM. *Pediatr Diabetes* 2010; **11**: 203-207 [PMID: 19686306 DOI: 10.1111/j.1399-5448.2009.00548.x]

3 **Polak M**, Cavé H. Neonatal diabetes mellitus: a disease linked to multiple mechanisms. *Orphanet J Rare Dis* 2007; **2**: 12 [PMID: 17349054 DOI: 10.1186/1750-1172-2-12]

4 **Varadarajan P**, Sangaralingam T, Senniappan S, Jahnavi S, Radha V, Mohan V. Clinical profile and outcome of infantile onset diabetes mellitus in southern India. *Indian Pediatr* 2013; **50**: 759-763 [PMID: 23502672]

5 **Ganesh R**, Arvindkumar R, Vasanthi T. Infantile-onset diabetes mellitus: a 1-year follow-up study. *Clin Pediatr* (Phila) 2009; **48**: 271-274 [PMID: 18836058 DOI: 10.1177/0009922808324950]

6 **De Franco E**, Flanagan SE, Houghton JA, Lango Allen H, Mackay DJ, Temple IK, Ellard S, Hattersley AT. The effect of early, comprehensive genomic testing on clinical care in neonatal diabetes: an international cohort study. *Lancet* 2015; **386**: 957-963 [PMID: 26231457]

7 **Holzinger A**, Bonfig W, Kusser B, Eggermann T, Müller H, Munch HG. Use of long-term microdialysis subcutaneous glucose monitoring in the management of neonatal diabetes. A first case report. *Biol Neonate* 2006; **89**: 88-91 [PMID: 16166771 DOI: 10.1159/000088349]

8 **von Mühlendahl KE**, Herkenhoff H. Long-term course of neonatal diabetes. *N Engl J Med* 1995; **333**: 704-708 [PMID: 7637748]

9 **Cavé H**, Polak M, Drunat S, Denamur E, Czernichow P. Refinement of the 6q chromosomal region implicated in transient neonatal diabetes. *Diabetes* 2000; **49**: 108-113 [PMID: 10615957]

10 **Temple IK**, Gardner RJ, Robinson DO, Kibirige MS, Ferguson AW, Baum JD, Barber JC, James RS, Shield JP. Further evidence for an imprinted gene for neonatal diabetes localised to chromosome 6q22-q23. *Hum Mol Genet* 1996; **5**: 1117-1121 [PMID: 8842729]

11 **Gardner RJ**, Mackay DJ, Mungall AJ, Polychronakos C, Siebert R, Shield JP, Temple IK, Robinson DO. An imprinted locus associated with transient neonatal diabetes mellitus. *Hum Mol Genet* 2000; **9**: 589-596 [PMID: 10699182]

12 **Temple IK**, Mackay D,Docherty LE**.** 6q24-Related Transient Neonatal Diabetes Mellitus**.** In: [Pagon RA](http://www.ncbi.nlm.nih.gov/pubmed?term=Pagon%20RA%5BEditor%5D), [Adam MP](http://www.ncbi.nlm.nih.gov/pubmed?term=Adam%20MP%5BEditor%5D), [Ardinger HH](http://www.ncbi.nlm.nih.gov/pubmed?term=Ardinger%20HH%5BEditor%5D), [Wallace SE](http://www.ncbi.nlm.nih.gov/pubmed?term=Wallace%20SE%5BEditor%5D), [Amemiya A](http://www.ncbi.nlm.nih.gov/pubmed?term=Amemiya%20A%5BEditor%5D), [Bean LJH](http://www.ncbi.nlm.nih.gov/pubmed?term=Bean%20LJH%5BEditor%5D), [Bird TD](http://www.ncbi.nlm.nih.gov/pubmed?term=Bird%20TD%5BEditor%5D), [Fong CT](http://www.ncbi.nlm.nih.gov/pubmed?term=Fong%20CT%5BEditor%5D), [Mefford HC](http://www.ncbi.nlm.nih.gov/pubmed?term=Mefford%20HC%5BEditor%5D), [Smith RJH](http://www.ncbi.nlm.nih.gov/pubmed?term=Smith%20RJH%5BEditor%5D), [Stephens K](http://www.ncbi.nlm.nih.gov/pubmed?term=Stephens%20K%5BEditor%5D), editors. GeneReviews®[Internet]. Seattle (WA): University of Washington, Seattle; 1993-2015. 2005 Oct 10 [updated 2015 Jan 15] [PMID: 20301706]

13 **Flanagan S**. Transient neonatal diabetes. Diapedia. Available from: URL: http://www.diapedia.org/41040851198/rev/23

14 **Gloyn AL**, Reimann F, Girard C, Edghill EL, Proks P, Pearson ER, Temple IK, Mackay DJ, Shield JP, Freedenberg D, Noyes K, Ellard S, Ashcroft FM, Gribble FM, Hattersley AT. Relapsing diabetes can result from moderately activating mutations in KCNJ11. *Hum Mol Genet* 2005; **14**: 925-934 [PMID: 15718250]

15 **Babenko AP**, Polak M, Cavé H, Busiah K, Czernichow P, Scharfmann R, Bryan J, Aguilar-Bryan L, Vaxillaire M, Froguel P. Activating mutations in the ABCC8 gene in neonatal diabetes mellitus. *N Engl J Med* 2006; **355**: 456-466 [PMID: 16885549]

16 **Proks P**, Arnold AL, Bruining J, Girard C, Flanagan SE, Larkin B, Colclough K, Hattersley AT, Ashcroft FM, Ellard S. A heterozygous activating mutation in the sulphonylurea receptor SUR1 (ABCC8) causes neonatal diabetes. *Hum Mol Genet* 2006; **15**: 1793-1800 [PMID: 16613899]

17 **Flanagan SE**, Patch AM, Mackay DJ, Edghill EL, Gloyn AL, Robinson D, Shield JP, Temple K, Ellard S, Hattersley AT. Mutations in ATP-sensitive K+ channel genes cause transient neonatal diabetes and permanent diabetes in childhood or adulthood. *Diabetes* 2007; **56**: 1930-1937 [PMID: 17446535]

18 **Schimmel U**. Long-standing sulfonylurea therapy after pubertal relapse of neonatal diabetes in a case of uniparental paternal isodisomy of chromosome 6. *Diabetes Care* 2009; **32**: e9 [PMID: 19114626]

19 **Poovazhagi V**, Thangavelu S. Relapsing Transient Neonatal Diabetes Mellitus due to ABCC8 Mutation. *J Mol Genet Med* 2014; **8**: 136 [DOI: 10.4172/1747-0862.1000136]

20 **Yorifuji T**, Hashimoto Y, Kawakita R, Hosokawa Y, Fujimaru R, Hatake K, Tamagawa N, Nakajima H, Fujii M. Relapsing 6q24-related transient neonatal diabetes mellitus successfully treated with a dipeptidyl peptidase-4 inhibitor: a case report. *Pediatr Diabetes* 2014; **15**: 606-610 [PMID: 24552466 DOI: 10.1111/pedi.12123]

21 **Pearson ER**, Flechtner I, Njølstad PR, Malecki MT, Flanagan SE, Larkin B, Ashcroft FM, Klimes I, Codner E, Iotova V, Slingerland AS, Shield J, Robert JJ, Holst JJ, Clark PM, Ellard S, Søvik O, Polak M, Hattersley AT. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. *N Engl J Med* 2006; **355**: 467-477 [PMID: 16885550]

22 **Nair VV**, Chapla A, Arulappan N, Thomas N. Molecular diagnosis of maturity onset diabetes of the young in India. *Indian J Endocrinol Metab* 2013; **17**: 430-441 [PMID: 23869298]

23 **Kochar IPS** and Kulkarni KP. Transient Neonatal Diabetes due to KCNJ11 Mutation. *Indian Pediatr* 2010; **47**: 359-360 [PMID: 20431170]

24 **Menon PS**, Khatwa UA. Diabetes mellitus in newborns and infants. *Indian J Pediatr* 2000; **67**: 443-448 [PMID: 10932965]

25 **Batra CM**, Gupta N, Atwal G, Gupta V. Transient neonatal diabetes due to activating mutation in the ABCC8 gene encoding SUR1. *Indian J Pediatr* 2009; **76**: 1169-1172 [PMID: 20092027]

26 **Rais N**, Joshi M. Transient neonatal diabetes mellitus. *Indian J Pediatr* 1988; **55**: 979-982 [PMID: 3235149]

27 **Kumar SS**, Premalatha G, Mohan V. Infantile Type 1 Diabetes Mellitus (Onset Less than One Year of Age) - A Report of Eight Patients. *Int J Diab Dev Ctries* 2002; **22**: 103-106

28 **Merchant R**, Irani A, Nagar P. Transient diabetes mellitus in early infancy. *Indian Pediatr* 1985; **22**: 529-532 [PMID: 3914466]

29 **Seth A**, Sharda S, Narula MK, Aneja S, Taluja V. Diabetes mellitus in an infant. *Indian J Pediatr* 2004; **71**: 947 [PMID: 15531847 DOI: 10.1007/BF02830846]

30 **Jali MV**, Patil VD, Jali SM, Gowda S, Kambar S. Type 1 diabetes mellitus with ketoacidosis in infancy. *Indian J Pediatr* 2009; **76**: 424-426 [PMID: 19205630]

31 **Flanagan S**. Permanent neonatal diabetes. Diapedia 2014. Available from: URL: http://www.diapedia.org/41040851200/rev/31

32 **De León DD**, Stanley CA. Permanent Neonatal Diabetes Mellitus. In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJH, Bird TD, Fong CT, Mefford HC, Smith RJH, Stephens K, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2015. 2008 Feb 8 [updated 2014 Jan 23] [PMID: 20301620]

33 **Zhang M**, Chen X, Shen S, Li T, Chen L, Hu M, Cao L, Cheng R, Zhao Z, Luo F. Sulfonylurea in the treatment of neonatal diabetes mellitus children with heterogeneous genetic backgrounds. *J Pediatr Endocrinol Metab* 2015; **28**: 877-884 [PMID: 25781672 DOI: 10.1515/jpem-2014-0429]

34 **Hattersley AH**, Ashcroft FM. Activating Mutations in Kir6.2 and Neonatal Diabetes. *Diabetes* 2005; **54**: 2503-2513 [DOI: 10.2337/diabetes.54.9.2503]

35 **Singh P**, Rao SC, Parikh R. Neonatal diabetes with intractable epilepsy: DEND syndrome. *Indian J Pediatr* 2014; **81**: 1387-1388 [PMID: 24912436]

36 **Letha S**, Mammen D, Valamparampil JJ. Permanent neonatal diabetes due to KCNJ11 gene mutation. *Indian J Pediatr* 2007; **74**: 947-949 [PMID: 17978456]

37 **Jain V**, Flanagan SE, Ellard S. Permanent neonatal diabetes caused by a novel mutation. *Indian Pediatr* 2012; **49**: 486-488 [PMID: 22796691]

38 **Joshi R**, Phatarpekar A. Neonatal diabetes mellitus due to L233F mutation in the KCNJ11 gene. *World J Pediatr* 2011; **7**: 371-372 [PMID: 21210267 DOI: 10.1007/s12519-011-0254-z]

39 **Slingerland AS**, Hurkx W, Noordam K, Flanagan SE, Jukema JW, Meiners LC, Bruining GJ, Hattersley AT, Hadders-Algra M. Sulphonylurea therapy improves cognition in a patient with the V59M KCNJ11 mutation. *Diabet Med* 2008; **25**: 277-281 [PMID: 18307455]

40 **Jahnavi S**, Poovazhagi V, Mohan V, Bodhini D, Raghupathy P, Amutha A, Suresh Kumar P, Adhikari P, Shriraam M, Kaur T, Das AK, Molnes J, Njolstad PR, Unnikrishnan R, Radha V. Clinical and molecular characterization of neonatal diabetes and monogenic syndromic diabetes in Asian Indian children. *Clin Genet* 2013; **83**: 439-445 [PMID: 22831748]

41 **Støy J**, Edghill EL, Flanagan SE, Ye H, Paz VP, Pluzhnikov A, Below JE, Hayes MG, Cox NJ, Lipkind GM, Lipton RB, Greeley SA, Patch AM, Ellard S, Steiner DF, Hattersley AT, Philipson LH, Bell GI. Insulin gene mutations as a cause of permanent neonatal diabetes. *Proc Natl Acad Sci USA* 2007; **104**: 15040-15044 [PMID: 17855560]

42 **Garin I**, Edghill EL, Akerman I, Rubio-Cabezas O, Rica I, Locke JM, Maestro MA, Alshaikh A, Bundak R, del Castillo G, Deeb A, Deiss D, Fernandez JM, Godbole K, Hussain K, O'Connell M, Klupa T, Kolouskova S, Mohsin F, Perlman K, Sumnik Z, Rial JM, Ugarte E, Vasanthi T, Johnstone K, Flanagan SE, Martínez R, Castaño C, Patch AM, Fernández-Rebollo E, Raile K, Morgan N, Harries LW, Castaño L, Ellard S, Ferrer J, Perez de Nanclares G, Hattersley AT. Recessive mutations in the INS gene result in neonatal diabetes through reduced insulin biosynthesis. *Proc Natl Acad Sci U S A* 2010; **107**: 3105-3110 [PMID: 20133622 DOI: 10.1073/pnas.0910533107]

43 **Ahamed A**, Unnikrishnan AG, Pendsey SS, Nampoothiri S, Bhavani N, Praveen VP, Kumar H, Jayakumar RV, Nair V, Ellard S, Edghill EL. Permanent neonatal diabetes mellitus due to a C96Y heterozygous mutation in the insulin gene. A case report. *JOP* 2008; **9**: 715-718 [PMID: 18981553]

44 **Turkkahraman D**, Bircan I, Tribble ND, Akçurin S, Ellard S, Gloyn AL. Permanent neonatal diabetes mellitus caused by a novel homozygous (T168A) glucokinase (GCK) mutation: initial response to oral sulphonylurea therapy. *J Pediatr* 2008; **153**: 122-126 [PMID: 18571549]

45 **Bennett K**, James C, Mutair A, Al-Shaikh H, Sinani A, Hussain K. Four novel cases of permanent neonatal diabetes mellitus caused by homozygous mutations in the glucokinase gene. *Pediatr Diabetes* 2011; **12**: 192-196 [PMID: 21518409]

46 **Stoffers DA**, Zinkin NT, Stanojevic V, Clarke WL, Habener JF. Pancreatic agenesis attributable to a single nucleotide deletion in the human IPF1 gene coding sequence. *Nat Genet* 1997; **15**: 106-110 [PMID: 8988180]

47 **De Franco E**, Shaw-Smith C, Flanagan SE, Shepherd MH, Hattersley AT, Ellard S. GATA6 mutations cause a broad phenotypic spectrum of diabetes from pancreatic agenesis to adult-onset diabetes without exocrine insufficiency. *Diabetes* 2013; **62**: 993-997 [PMID: 23223019 DOI: 10.2337/db12-0885]

48 **Hoveyda N**, Shield JP, Garrett C, Chong WK, Beardsall K, Bentsi-Enchill E, Mallya H, Thompson MH. Neonatal diabetes mellitus and cerebellar hypoplasia/agenesis: report of a new recessive syndrome. *J Med Genet* 1999; **36**: 700-704 [PMID: 10507728]

49 **Rubio-Cabezas O**, Minton JA, Caswell R, Shield JP, Deiss D, Sumnik Z, Cayssials A, Herr M, Loew A, Lewis V, Ellard S, Hattersley AT. Clinical heterogeneity in patients with FOXP3 mutations presenting with permanent neonatal diabetes. *Diabetes Care* 2009; **32**: 111-116 [PMID: 18931102]

50 **Senée V**, Chelala C, Duchatelet S, Feng D, Blanc H, Cossec JC, Charon C, Nicolino M, Boileau P, Cavener DR, Bougnères P, Taha D, Julier C. Mutations in GLIS3 are responsible for a rare syndrome with neonatal diabetes mellitus and congenital hypothyroidism. *Nat Genet* 2006; **38**: 682-687 [PMID: 16715098]

51 **Concepcion JP**, Reh CS, Daniels M, Liu X, Paz VP, Ye H, Highland HM, Hanis CL, Greeley SA. Neonatal diabetes, gallbladder agenesis, duodenal atresia, and intestinal malrotation caused by a novel homozygous mutation in RFX6. *Pediatr Diabetes* 2014; **15**: 67-72 [PMID: 23914949]

52 **Rubio-Cabezas O**, Minton JA, Kantor I, Williams D, Ellard S, Hattersley AT. Homozygous mutations in NEUROD1 are responsible for a novel syndrome of permanent neonatal diabetes and neurological abnormalities. *Diabetes* 2010; **59**: 2326-2331 [PMID: 20573748 DOI: 10.2337/db10-0011]

53 **Pinney SE**, Oliver-Krasinski J, Ernst L, Hughes N, Patel P, Stoffers DA, Russo P, De León DD. Neonatal diabetes and congenital malabsorptive diarrhea attributable to a novel mutation in the human neurogenin-3 gene coding sequence. *J Clin Endocrinol Metab* 2011; **96**: 1960-1965 [PMID: 21490072]

54 **Ganesh R**, Ezhilarasi S, Vasanthi T, Gowrishankar K, Rajajee S. Thiamine responsive megaloblastic anemia syndrome. *Indian J Pediatr* 2009; **76**: 313-314 [PMID: 19347672]

55 **Shaw-Smith C**, Flanagan SE, Patch AM, Grulich-Henn J, Habeb AM, Hussain K, Pomahacova R, Matyka K, Abdullah M, Hattersley AT, Ellard S. Recessive SLC19A2 mutations are a cause of neonatal diabetes mellitus in thiamine-responsive megaloblastic anaemia. *Pediatr Diabetes* 2012; **13**: 314-321 [PMID: 22369132]

56 **Poovazhagi V**, Sridhurga U, Prabha S, Sujatha J. A Novel Mutation in the GLUT2 gene – Case report of Fanconi-Bickel Syndrome in a Female Indian Patient. *J Hypo Hyperglycemia* 2015; **2**: 1 [DOI: 10.4172/2327-4700.1000106]

57 **Poovazhagi V**, Shanthi S, Jahnavi S, Radha V, Mohan V. Berardinelli Seip congenital lipodystrophy presenting with neonatal diabetes mellitus due to a mutation in the AGPAT2 gene. *Int J Diabetes Dev Ctries* 2013; **33**: 129-129 [DOI: 10.1007/s13410-012-0099-6]

58 **Tubiana-Rufi N**. Insulin pump therapy in neonatal diabetes. *Endocr Dev* 2007; **12**: 67-74 [PMID: 17923770]

59 **Beardsall K**, Pesterfield CL, Acerini CL. Neonatal diabetes and insulin pump therapy. *Arch Dis Child Fetal Neonatal Ed* 2011; **96**: F223-F224 [PMID: 21115555]

60 **Hattersely AT**. Transferring patients who have a mutation in KCJ11 or ABCC8. Available from: URL: http://www.diabetesgenes.org/content/transferring-patients-who-have-mutation-kcnj11-or-abcc8

61 **Poovazhagi V**, Muralidharan PS, Parivathini S. Neonatal diabetes with KIR 6.2 mutation on glibenclamide therapy. *Pediatric Oncall* [serial online] 2012 [cited 2012 Apr 1]; 9. Art #23. Available from: URL: http://www.pediatriconcall.com/Journal/Article/FullText.aspx?artid=473&type=J&tid=&imgid=&reportid=52&tbltype=

62 **Codner E**, Flanagan S, Ellard S, García H, Hattersley AT. High-dose glibenclamide can replace insulin therapy despite transitory diarrhea in early-onset diabetes caused by a novel R201L Kir6.2 mutation. *Diabetes Care* 2005; **28**: 758-759 [PMID: 15735229]

63 **Sagen JV**, Raeder H, Hathout E, Shehadeh N, Gudmundsson K, Baevre H, Abuelo D, Phornphutkul C, Molnes J, Bell GI, Gloyn AL, Hattersley AT, Molven A, Søvik O, Njølstad PR. Permanent neonatal diabetes due to mutations in KCNJ11 encoding Kir6.2: patient characteristics and initial response to sulfonylurea therapy. *Diabetes* 2004; **53**: 2713-2718 [PMID: 15448106]

64 **Slingerland AS**, Nuboer R, Hadders-Algra M, Hattersley AT, Bruining GJ. Improved motor development and good long-term glycaemic control with sulfonylurea treatment in a patient with the syndrome of intermediate developmental delay, early-onset generalised epilepsy and neonatal diabetes associated with the V59M mutation in the KCNJ11 gene. *Diabetologia* 2006; **49**: 2559-2563 [PMID: 17047922]

65 **Zung A**, Glaser B, Nimri R, Zadik Z. Glibenclamide treatment in permanent neonatal diabetes mellitus due to an activating mutation in Kir6.2. *J Clin Endocrinol Metab* 2004; **89**: 5504-5507 [PMID: 15531505]

66 **Klupa T**, Edghill EL, Nazim J, Sieradzki J, Ellard S, Hattersley AT, Malecki MT. The identification of a R201H mutation in KCNJ11, which encodes Kir6.2, and successful transfer to sustained-release sulphonylurea therapy in a subject with neonatal diabetes: evidence for heterogeneity of beta cell function among carriers of the R201H mutation. *Diabetologia* 2005; **48**: 1029-1031 [PMID: 15838686]

67 **Carmody D**, Bell CD, Hwang JL, Dickens JT, Sima DI, Felipe DL, Zimmer CA, Davis AO, Kotlyarevska K, Naylor RN, Philipson LH, Greeley SA. Sulfonylurea treatment before genetic testing in neonatal diabetes: pros and cons. *J Clin Endocrinol Metab* 2014; **99**: E2709-E2714 [PMID: 25238204 DOI: 10.1210/jc.2014-2494]

68 **Thurber BW**, Carmody D, Tadie EC, Pastore AN, Dickens JT, Wroblewski KE, Naylor RN, Philipson LH, Greeley SA. Age at the time of sulfonylurea initiation influences treatment outcomes in KCNJ11-related neonatal diabetes. *Diabetologia* 2015; **58**: 1430-1435 [PMID: 25877689 DOI: 10.1007/s00125-015-3593-9]

69 **Kumaraguru J**, Flanagan SE, Greeley SA, Nuboer R, Støy J, Philipson LH, Hattersley AT, Rubio-Cabezas O. Tooth discoloration in patients with neonatal diabetes after transfer onto glibenclamide: a previously unreported side effect. *Diabetes Care* 2009; **32**: 1428-1430 [PMID: 19435956 DOI: 10.2337/dc09-0280]

**P-Reviewer:** Lin GM, Puddu PE **S-Editor:** Ji FF **L-Editor: E-Editor:**

**Table 1 Diagnostic clues for type of mutation in infantile onset diabetes mellitus**

|  |  |
| --- | --- |
| Associated features  | Diagnostic possibility of mutation |
| Umbilical hernia, macroglossia | 6q 24  |
| Developmental delay | KCNJ11, ABCC8, EIF2AK3  |
| Microcephaly | PTF 1A |
| Hypothyroidism | EIF2AK3, GLIS 3, FOXP3 |
| Diarrhea, eczema | IPEX |
| Anemia | EIF2AK3, SLC19A2 |
| Hepatomegaly with liver dysfunction | EIF2AK3 |
| Cerebellar hypoplasia | PTF1A, NEUROD 1 |
| Pancreatic hypoplasia | RFX 6, HNF1B, PTF1A, GATA6  |
| Ocular manifestations | PAX 6 |
| Rickets, round facies, mild hyperglycemia  | SLC2A2 |
| No syndromic features | KCNJ11, ABCC8, INS |
| Renal abnormalities | GLIS3, HNF1B |
| Hirsutism, failure to thrive | Insulin resistance syndromes |

KCNJ11: Potassium channel subfamily J member 11; ABCC8: ATP binding cassette transporter subfamily C, member 8; EIF2AK3: Eukaryotic translation initiation factor - 2 kinase; PTF: Pancreatic transcription factor; GLIS3: GLI subfamily of Kruppel-like zinc finger protein-3; SLC2A2: Solute carrier 2 family 2 gene; INS: Insulin.